A Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...
Irish Independent on MSN1d
‘I am the luckiest person in the world’ – Kilkenny businesswoman on living with multiple myelomaWhen Mags Kirwan was first diagnosed with multiple myeloma three years ago, she made the conscious decision to “run her own journey” and not let her diagnosis dictate her future. Since then, the ...
During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...
During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...
"Cancer changes some things, of that there is no doubt. And, some things it takes away. Yet, at the same time, cancer can ...
Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...
The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...
Researchers sought to determine whether fixed-duration therapy would still be feasible for patients with RRMM who were treated with a bispecific antibody in clinical trials and discontinued.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback